title: A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer.
abstract: OBJECTIVE
  To determine the anti-tumor activity DX-8951f when administered as a 30-minute infusion daily for 5 days every 3 weeks to patients with previously untreated metastatic gastric cancer, and to evaluate toxicities and pharmacokinetics (PK) of DX-8951f in this patient population.
  
  
  METHODS
  Forty-one patients were enrolled. All had previously untreated metastatic gastric cancer. DX-8951f was administered until disease progression or unacceptable toxicity. Responses were assessed after every 2 courses using RECIST criteria.
  
  
  RESULTS
  Thirty-nine patients were evaluable. Two patients achieved a partial response (PR) and 18 achieved stable disease (SD), including five patients with unconfirmed PR. A total of 141 courses of therapy were delivered (median 3, range 1-10). The most common drug-related toxicity was neutropenia. Non-hematologic toxicities were mostly mild to moderate; the most common were nausea, vomiting and anorexia. Plasma concentrations of DX-8951 (the anhydrous form of DX-8951f) were well described using a linear 2-compartment PK model. All concentrations and dose events were simultaneously modeled and explained by the population PK model. There was no evidence of non-linearity in the elimination PK, auto-inhibition or induction of DX-8951 clearance over the five days of administration.
  
  
  CONCLUSIONS
  DX-8951f had modest activity against metastatic gastric cancer and its PK was dose-proportional. The toxicity profile was predictable and manageable. Further development of this agent is warranted.
authors.affiliation: M.D. Anderson Cancer Center, The University of Texas, 1515 Holcombe Boulevard, Box 426, Houston, TX, 77030, USA. jajani@mdanderson.org
authors.forename: Jaffer A
authors.initials: JA
authors.lastname: Ajani
authors.forename: Chris
authors.initials: C
authors.lastname: Takimoto
authors.forename: Carlos R
authors.initials: CR
authors.lastname: Becerra
authors.forename: Alejandro
authors.initials: A
authors.lastname: Silva
authors.forename: Luis
authors.initials: L
authors.lastname: Baez
authors.forename: Allen
authors.initials: A
authors.lastname: Cohn
authors.forename: Pierre
authors.initials: P
authors.lastname: Major
authors.forename: Makio
authors.initials: M
authors.lastname: Kamida
authors.forename: Kevie
authors.initials: K
authors.lastname: Feit
authors.forename: Robert
authors.initials: R
authors.lastname: De Jager
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; C095887:exatecan; D002166:Camptothecin